MedTrace Logo

A Study to Test the Safety of Three Experimental HIV Vaccines

NCT00000946 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-10-29

No results posted yet for this study

Summary

The purpose of this study is to test three experimental HIV vaccines. This study will look at whether it is safe to give these vaccines together and how the immune system responds to the vaccines.

There are a number of studies being performed to test HIV vaccines. The vaccines that seem to be the most promising are canarypox vaccines, known as ALVAC vaccines. The three experimental HIV vaccines used in this study are called ALVAC-HIV vCP205, HIV-1 SF-2 p24, and HIV-1 SF-2 rgp120. The HIV-1 SF-2 p24 and HIV-1 SF-2 rgp120 vaccines are mixed with an adjuvant, which is a substance that increases immune response.

Conditions

  • HIV Infections
  • HIV Seronegativity

Interventions

BIOLOGICAL

HIV p24/MF59 Vaccine

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

BIOLOGICAL

rgp120/HIV-1 SF-2

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Mark J Mulligan, MD · Univ of Alabama at Birmingham

Study Design

Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Completion
2001-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000946 on ClinicalTrials.gov